Research has been done on the interaction between amphetamines and The Cytochrome P450 CYP2D6 enzyme, and researchers concluded that some parts of substrate molecules contribute to the binding of the enzyme.
Additional drugs found to be affected by grapefruit juice include, but are not limited to:
cyclosporine (Neoral): Blood levels of cyclosporine are increased if taken with grapefruit juice. A plausible mechanism involves the combined inhibition of enteric CYP3A4 and P-glycoprotein, which potentially leads to serious adverse events (e.g., nephrotoxicity). Blood levels of tacrolimus (Prograf) can also be equally affected for the same reason as cyclosporine, as both drugs are calcineurin inhibitors.
exemestane, aromasin, and by extension all estrogen-like compounds and aromatase inhibitors which mimic estrogen in function will be increased in effect, causing increased estrogen retention and increased drug retention.
imatinib (Gleevec): Although no formal studies with imatinib and grapefruit juice have been conducted, the fact that grapefruit juice is a known inhibitor of the CYP 3A4 suggests that co-administration may lead to increased imatinib plasma concentrations. Likewise, although no formal studies were conducted, co-administration of imatinib with another specific type of citrus juice called Seville orange juice (SOJ) may lead to increased imatinib plasma concentrations via inhibition of the CYP3A isoenzymes. Seville orange juice is not usually consumed as a juice because of its sour taste, but it is found in marmalade and other jams. Seville orange juice has been reported to be a possible inhibitor of CYP3A enzymes without affecting P-glycoprotein when taken concomitantly with cyclosporine.
The CYP3A4 isoform of cytochrome P450 is located in both the liver and the enterocytes. Many oral drugs undergo first-pass (presystemic) metabolism by the enzyme. Several organic compounds found in grapefruit and specifically in grapefruit juice exert inhibitory action on drug metabolism by the enzyme. It has been established that a group of compounds called furanocoumarins are responsible for this interaction, and not flavonoids as was previously reported. The list of active furanocoumarins found in grapefruit juice includes: bergamottin, bergapten, bergaptol and 6',7'-dihydroxybergamottin.
This interaction is particularly dangerous when the drug in question has a low therapeutic index, so that a small increase in blood concentration can be the difference between therapeutic effect and toxicity. Grapefruit juice inhibits the enzyme only within the intestines if consumed in low amounts. Intestinal enzyme inhibition will only affect the potency of orally administrated drugs. When larger amounts of grapefruit are consumed it may also inhibit the enzyme in the liver. The hepatic enzyme inhibition may cause an additional increase in potency and a prolonged metabolic half-life (prolonged metabolic half-life for all ways of drug administration). The degree of the effect varies widely between individuals and between samples of juice, and therefore cannot be accounted for a priori.
Another mechanism of interaction is possibly through the P-glycoprotein (Pgp) that is localized in the apicalbrush border of the enterocytes. Pgp transports lipophilic molecules out of the enterocyte back into the intestinal lumen. Drugs that possess lipophilic properties are either metabolised by CYP3A4 or removed into the intestine by the Pgp transporter. Both the Pgp and CYP3A4 may act synergistically as a barrier to many orally administered drugs. Therefore, their inhibition (both or alone) can markedly increase the bioavailability of a drug.
The interaction caused by grapefruit compounds lasts for up to 72 hours, and its effect is the greatest when the juice is ingested with the drug or up to 4 hours before the drug.
^Sugimoto K, Araki N, Ohmori M, et al. (March 2006). "Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam". European Journal of Clinical Pharmacology62 (3): 209–15. doi:10.1007/s00228-005-0071-1. PMID16416305.
^Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BC (November 1999). "The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study". Clinical Therapeutics21 (11): 1890–9. doi:10.1016/S0149-2918(00)86737-5. PMID10890261.
^Lilja JJ, Kivistö KT, Neuvonen PJ (August 1999). "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin". Clinical Pharmacology and Therapeutics66 (2): 118–27. doi:10.1053/cp.1999.v66.100453001. PMID10460065.
^Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ (December 1998). "Grapefruit juice substantially increases plasma concentrations of buspirone". Clinical Pharmacology and Therapeutics64 (6): 655–60. doi:10.1016/S0009-9236(98)90056-X. PMID9871430.
^Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. (January 2002). "Effects of grapefruit juice on the pharmacokinetics of sildenafil". Clinical Pharmacology and Therapeutics71 (1): 21–9. doi:10.1067/mcp.2002.121236. PMID11823754.
^Gasche Y, Daali Y, Fathi M, et al. (December 2004). "Codeine intoxication associated with ultrarapid CYP2D6 metabolism". The New England Journal of Medicine351 (27): 2827–31. doi:10.1056/NEJMoa041888. PMID15625333.
^Benmebarek M, Devaud C, Gex-Fabry M, et al. (July 2004). "Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone". Clinical Pharmacology and Therapeutics76 (1): 55–63. doi:10.1016/j.clpt.2004.03.007. PMID15229464.
^Dasgupta A, Reyes MA, Risin SA, Actor JK (December 2008). "Interaction of white and pink grapefruit juice with acetaminophen (paracetamol) in vivo in mice". Journal of Medicinal Food11 (4): 795–8. doi:10.1089/jmf.2008.0059. PMID19053875.
^Dresser GK, Kim RB, Bailey DG (March 2005). "Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides". Clinical Pharmacology and Therapeutics77 (3): 170–7. doi:10.1016/j.clpt.2004.10.005. PMID15735611.
^Jellin J.M., et al. Pharmacist's Letter/Prescriber's Letter of Natural Medicines Comprehensive Database. 7th ed. Stockton, CA: Therapeutic Research Faculty. 2005. 626-629
^Veronese ML, Gillen LP, Burke JP, et al. (August 2003). "Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice". Journal of Clinical Pharmacology43 (8): 831–9. doi:10.1177/0091270003256059. PMID12953340.
^Lundahl J, Regårdh CG, Edgar B, Johnsson G (1995). "Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects". European Journal of Clinical Pharmacology49 (1-2): 61–7. doi:10.1007/BF00192360. PMID8751023.
^Greenblatt DJ, von Moltke LL, Harmatz JS, et al. (August 2003). "Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice". Clinical Pharmacology and Therapeutics74 (2): 121–9. doi:10.1016/S0009-9236(03)00118-8. PMID12891222.
Murray M (July 2006). "Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents". The Journal of Pharmacy and Pharmacology58 (7): 871–85. doi:10.1211/jpp.58.7.0001. PMID16805946.
Zanger UM, Turpeinen M, Klein K, Schwab M (November 2008). "Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation". Analytical and Bioanalytical Chemistry392 (6): 1093–108. doi:10.1007/s00216-008-2291-6. PMID18695978.
Fasinu P, Choonara YE, Khan RA, et al. (February 2013). "Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability". Journal of Pharmaceutical Sciences102 (2): 541–55. doi:10.1002/jps.23382. PMID23188647.